Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

How Much Can Trump’s Childhood Cancer Funding Proposal Boost Drug Approvals?

Feb 06 2019

• By Michael Cipriano

State of the Union

Related Content

The Cost Of Drug Development: Can We All Just Agree It’s Expensive?

Sep 14 2017

Sen. Grassley To Be "More Insistent" About Drug Firms' Testimony At Future Hearings

Jan 30 2019

US FDA’s Best Year Ever For New Drugs: CDER Novel Approvals Hit 59

Jan 01 2019

Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

Nov 07 2018

Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

Oct 26 2018

Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely

Jan 11 2019

Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago

Mar 26 2017

Related Companies

Stemline Therapeutics, Inc.

Les Laboratoires Servier

Loxo Oncology at Lilly

Merck KGaA

Pfizer Inc.

AbbVie Inc.

AstraZeneca PLC

Bristol Myers Squibb Company

Johnson & Johnson

Merck & Co., Inc.

Sanofi

Additional Topics

United States Research & Development Pricing Debate Policy BioPharmaceutical Cancer Infectious Diseases

More from R&D

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window